Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02886065CT.gov A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Smoldering Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Citarinostat (this asset) | Massachusetts General Hospital | P1 | CC · 41 |
| Dexasone | Regeneron Pharmaceuticals | P3 | BB |
| Nivestim | Regeneron Pharmaceuticals | P3 | BB |
| Lenalidomide | Irene Ghobrial, MD | P3 | BB |
| Linvoseltamab | Regeneron Pharmaceuticals | P3 | BB |
| Daratumumab | Regeneron Pharmaceuticals | P3 | BB |
| Cyclophosphamide | Dana-Farber Cancer Institute | P2 | B |
| Melphalan | PETHEMA Foundation | P3 | B |
| Bortezomib | Omar Nadeem, MD | P2 | B |
+39 more in the Smoldering Plasma Cell Myeloma cohort
Other indications for Citarinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P1 | CC · 44 |
| Cancer | — | P1 | C · 39 |
| Non-Small Cell Lung Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Citarinostat in Smoldering Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/citarinostat-smoldering-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →